AltrixBio: Valuation, Funding & Investors
AltrixBio is a biopharmaceutical company focused on developing innovative treatments for cardiometabolic diseases. The company's lead candidate, AJN 003 (LuCI™), is a first-in-class oral therapy designed to replicate the metabolic benefits of bariatric surgery without the associated risks, targeting type 2 diabetes, obesity, and other metabolic disorders. Founded in 2019, AltrixBio leverages research from Mass General Brigham and Harvard Medical School to create novel, patent-protected therapies aimed at transforming the treatment landscape for these conditions.
Leadership & Board
- Current Number of Employees
- 6
- Current LinkedIn Followers
- 942
Latest Estimated Valuation
- Total Amount Raised
- $5M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $5M
- Latest Funding Round
- Series A
Employee Trend
AltrixBio had 6 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
AltrixBio had 942 followers as of November 9, 2026. The number of followers increased by 1 (0.11%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 16, 2025 | Series A | $5.00M | ― |
Similar Companies
A snapshot of private companies similar to AltrixBio, helping you discover and navigate related company profiles.
